Follistatin-like protein 3 (FSTL3)

Follistatin-like protein 3 (FSTL3) is a member of the follistatin-module-protein family, encoding a secreted glycoprotein that acts as an inhibitor of TGF-β family ligands (notably activin and myostatin)[1][2][3]. FSTL3 is expressed in tissues such as the heart, placenta, gonads, pancreas, and reproductive organs, where it regulates cellular differentiation, apoptosis, and reproductive cycles[1][4]. It plays a role in several pathological processes including carcinogenesis, cardiovascular diseases, and inflammation, making it a potential therapeutic target and biomarker in these fields[1][2][3]. FSTL3 binds activin and myostatin, preventing their signaling and thereby influencing cell growth and tissue homeostasis[1][2]. Elevated or dysregulated FSTL3 expression is associated with metastatic progression, tumor suppression, and chronic diseases[1][3][4].

Other names

Follistatin-related protein 3FSTL3

Drugs or molecules that would inhibit FSTL3 would likely modulate TGF-β family ligand signaling pathways (especially activin and myostatin signaling)